Patritumab deruxtecan (U3-1402/ MK-1022) is an experimental antibody–drug conjugate developed by Merck and Daiichi Sankyo to treat non-small-cell lung cancer.
The compounds of every Wikipedia article carrying a Chembox or a Drugbox, refreshed daily, with the values their infoboxes give. The pages need JavaScript; the API does not.